Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2021 - 2025)

Historic Operating Leases for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $7.0 million.

  • Kiniksa Pharmaceuticals International's Operating Leases fell 1800.56% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 1800.56%. This contributed to the annual value of $7.9 million for FY2024, which is 2141.93% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Operating Leases of $7.0 million as of Q3 2025, which was down 1800.56% from $7.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Operating Leases' 5-year high stood at $11.3 million during Q2 2023, with a 5-year trough of $1.3 million in Q2 2022.
  • For the 5-year period, Kiniksa Pharmaceuticals International's Operating Leases averaged around $6.0 million, with its median value being $7.0 million (2025).
  • In the last 5 years, Kiniksa Pharmaceuticals International's Operating Leases crashed by 6348.57% in 2022 and then soared by 78286.38% in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Leases (Quarter) stood at $2.7 million in 2021, then dropped by 1.91% to $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then fell by 21.42% to $7.9 million in 2024, then dropped by 10.68% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $7.2 million for Q2 2025, and $7.6 million during Q1 2025.